San Diego, October 2, 2024 – EpicentRx today announce its lead small molecule, RRx-001 (nibrozetone), is the subject of an oral nanosymposium session in amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) at the 2024 Society for Neuroscience (SfN) during the ALS Therapeutic session happening on October 9th in Chicago, IL.
Dr. Richard Gordon, A/Prof. from the Queensland University of Technology’s Translational Research Institute (QUT-TRI), will present compelling preclinical data with RRx-001 in ALS/MND, a fatal type of neurodegenerative disease characterized by progressive muscular paralysis and no real effective treatments, from his lab.
EpicentRx and Dr. Gordon have been awarded several prestigious grants from the Michael J. Fox Foundation, the US Department of Defense (DoD) and others to investigate the activity of lead EpicentRx small molecule, RRx-001 (nibrozetone), in several ND indications including Parkinson’s, Amyotrophic Lateral Sclerosis (ALS)/Motor Neurone Disease (MND), and central nervous system (CNS) toxic exposures.
Details about the SfN presentation are below:
Session Type: Nanosymposium
Session Number: NANO51
Session Title: ALS Therapeutics
Location/Room: MCP Room N427
Presentation Date and Time: 10/9/2024 9:00 AM – 9:15 AM CT
About EpicentRx:
EpicentRx Incorporated is a privately held biopharmaceutical company with two innovative-driven platforms of which nibrozetone (RRx-001) and AdAPT-001 are the lead compounds, respectively. The company’s mission is disease remission, which it hopes to accomplish with novel, well-tolerated therapies that target a diverse range of unmet needs in cancer and non-cancer indications. Nibrozetone (RRx-001), a multimechanistic small molecule, is designed and currently under clinical investigation to preferentially target diseased tissues like tumors even as it shields normal cells from harm. A late-stage clinical trial named KEVLARx is currently ongoing for protection against chemoradiation-induced oral mucositis in first line head and neck cancer. Learn more at https://www.epicentrx.com.
Media Contact:
Ashley Thomaz
Email: ashleyt@mcspr.com